The third episode of our podcast, ImmortaliCast, is now available! We interviewed Didier Coeurnelle, chair and co-founder of HEALES, and Marion Steenacker, biologist from HEALES, who updated us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES. Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

You can watch this episode via YouTube or on the main podcast platforms:

#science #rejuvenation #aging #medicine #health #heales #lifespan #biology #plasma #HaroldKatcher #RodolfoGoya

---

In this interview for the podcast ImmortaliCast, Didier Coeurnelle, chair and co-founder of HEALES (https://heales.org/), and Marion Steenacker, biologist from HEALES, update us on the partial results from the lifespan experiments on rats conducted by Harold Katcher and Rodolfo Goya and funded by HEALES (https://heales.org/2020/12/22/studies-financed-by-heales-eff…er-2020/). Didier also discusses the more important trends in the rejuvenation field, and the other activities and goals of HEALES.

The Fable of the Dragon-Tyrant:

Papers referenced in the video:

Remnant Cholesterol and Atherosclerotic Cardiovascular Disease Risk:
https://www.jacc.org/doi/10.1016/j.jacc.2020.10.

The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling:
https://www.sciencedirect.com/science/article/pii/S0753332220309781

Joint distribution of lipoprotein cholesterol classes. The Framingham study:
https://pubmed.ncbi.nlm.nih.gov/6573877/

Long-term coronary heart disease risk associated with very-low-density lipoprotein cholesterol in Chinese: the results of a 15-Year Chinese Multi-Provincial Cohort Study (CMCS):
https://pubmed.ncbi.nlm.nih.gov/20223457/

Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease:

A handful of companies are trying vastly different approaches to spin animal studies into the next big anti-aging therapy.

While the mitochondrion has long fascinated biologists and the sheer diversity of druggable targets has made it attractive for potential drug development, there has been little success translatable to the clinic. Given the diversity of inborn errors of metabolism and mitochondrial diseases, mitochondrially mediated oxidative stress (myopathies, reperfusion injury, Parkinson’s disease, ageing) and the consequences of disturbed energetics (circulatory shock, diabetes, cancer), the potential for meaningful gain with novel drugs targeting mitochondrial mechanisms is huge both in terms of patient quality of life and health care costs. In this themed issue of the British Journal of Pharmacology, we highlight the key directions of the contemporary advances in the field of mitochondrial biology, emerging drug targets and new molecules which are close to clinical application. Authors’ contributions are diverse both in terms of species and organs in which the mitochondrially related studies are performed, and from the perspectives of mechanisms under study. Defined roles of mitochondria in disease are updated and previously unknown contributions to disease are described in terms of the interface between basic science and pathological relevance.

Getting older is a fact of life. As we age, we can grow bigger, smarter and stronger. But at a certain point, our bodies often start to slow down. The idea behind why we age and why our bodies slow down is that we start to lose the ability to make enough energy to support all the different functions that our body carries out.

Hazel H. Szeto, MD, PhD, is a medical doctor and a research scientist. She may have found the answer to reversing the aging process by restoring a person’s ability to make energy. Szeto presented her work last month at Experimental Biology 2021.

To better understand Szeto’s discovery, we must first understand how the body makes energy. We produce energy in the form of a small molecule called adenosine triphosphate, or ATP. When ATP is broken down, it releases energy that allows our bodies to do work, such as contracting the muscles in our arms and legs so we can lift a box. Mitochondria are small structures in the cells that make ATP from the food we eat.

A clinical-stage leader in immune-stimulatory vaccines for cancer announced the publication of its favorable long-term Overall Survival (OS) data from a Phase I trial evaluating a universal cancer vaccine candidate, UV1, in combination with checkpoint inhibitor ipilimumab, in patients with metastatic malignant melanoma.

UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.

Published in the Frontiers in Immunology journal on May 11, 2021, Norway-based Ultimovacs ASA’s UV1 vaccine candidate achieved the primary endpoints of safety and tolerability.